Lambrinex

Atorvastatin, the active ingredient in Lambrinex, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol levels and is used in adults with hypercholesterolemia, mixed dyslipidemia, and for cardiovascular disease prevention. GNH USA supplies Lambrinex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin acts on lipid metabolism pathways to manage abnormal cholesterol and reduce cardiovascular risk. - Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Mixed dyslipidemia: reduces LDL and triglycerides while modestly increasing high‑density lipoprotein (HDL) cholesterol. - Primary and secondary prevention of cardiovascular disease: decreases the incidence of myocardial infarction, stroke and cardiovascular mortality in at‑risk patients.

Adverse reactions may occur with atorvastatin therapy.

Common Side Effects: - Muscle aches or weakness - Headache - Nausea or abdominal discomfort - Constipation or diarrhea - Elevated liver enzymes (transaminases) - Dizziness

Serious or Rare Side Effects: - Rhabdomyolysis with severe muscle breakdown - Acute liver injury or hepatitis - Severe allergic reactions such as rash, angioedema or anaphylaxis - Myopathy with marked creatine kinase elevation - Pancreatitis - Renal impairment secondary to muscle breakdown

Before initiating therapy, consider the following safety measures. - Liver function monitoring: assess baseline transaminases and repeat periodically. - Muscle symptom assessment: educate patients to report unexplained muscle pain or weakness. - Drug review: evaluate concurrent medications that may increase statin exposure. - Renal function: adjust use in patients with severe renal impairment. - Pregnancy and lactation: avoid use unless potential benefit justifies the risk. - Store at room temperature: keep in the original container, protect from moisture and heat.

Atorvastatin may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, HIV protease inhibitors). - Gemfibrozil or high‑dose niacin. - Cyclosporine or colchicine.

Moderate Interactions (Monitor Closely): - Calcium channel blockers such as amlodipine. - Anticoagulants like warfarin. - Digoxin and certain macrolide antibiotics.